| Date | Title | Description |
| 12.05.2026 | Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 | Boston – MAY 12, 2026 – Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced completion of patient enrollment in the pivotal Phase 3 ARISE trial evalu... |
| 28.04.2026 | Lighthouse Pharmaceuticals: $12 Million Raised For Targeting Alzheimer’s Disease | Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative and inflammatory diseases, has closed a $12 million Series A financing round led by Double Point Ventures, with... |
| 20.01.2025 | Umoja Biopharma's $100 Million Leap: A New Era for In Vivo CAR T Cell Therapies | Umoja Biopharma is on the rise. The Seattle-based company has just secured $100 million in Series C financing. This is not just a number; it’s a statement. It signals a bold step forward in the world of biotechnology. The funding round was ... |
| 20.01.2025 | Umoja Biopharma Raises $100M in Series C Financing | Umoja Biopharma, a Seattle, WA-based clinical-stage company which specializes in vivo cell therapies, raised $100M Series C financing.
The round was led by Double Point Ventures and DCVC Bio, with participation from new and existing investo... |
| 18.09.2024 | Immunos Therapeutics raises USD11 million |
ImmunOs’ lead program IOS-1002 is currently tested in a Phase Ia dose escalation clinical trial as a monotherapy and in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). IOS-1002 is a novel, multifunctional immunotherapy a... |
| 15.06.2024 | Eko Health: $41 Million Closed To Scale AI-Based Heart And Lung Disease Detection Technology | Eko Health, a company that is applying artificial intelligence for early detection of heart and lung diseases, announced it has raised $41 million in Series D financing. With participation from ARTIS Ventures, Highland Capital Partners, NTT... |
| 25.04.2024 | Cerevance Secures $47M to Drive Innovation in CNS Therapeutics | Cerevance, a Boston-based company specializing in precision treatments for central nervous system (CNS) disorders, recently closed a $47 million Series B-1 Extension financing round. The funding, led by Agent Capital, Bioluminescence Ventur... |
| 25.04.2024 | Cerevance Raises $47M in Series B-1 Extension | Cerevance, a Boston, MA-based company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, raised $47M in Series B-1 Extension.
The round was led by Agent Capital, Bioluminescence Ventures, and Doubl... |